Evidence map›Paper›PMID 34576808›Full record

ArticleMicroorganisms2021

Characterization of ESBL-Producing

Isabel Carvalho, José António Carvalho, Sandra Martínez-Álvarez, Madjid Sadi, Rosa Capita, Carlos Alonso-Calleja, Fazle Rabbi, Maria de Lurdes Nunes Enes Dapkevicius, Gilberto Igrejas, Carmen Torres and 1 more

Abstract read
In one paragraph

Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Prevalence of ESBL-producingOne health (Amsterdam, Netherlands) · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. CombatingFrontiers in cellular and infection microbiology · 2025
    Review
  10. Article
  11. Article
  12. AmpC β-lactamases detected in Southeast AsianJAC-antimicrobial resistance · 2024
    Article
  13. Article
  14. Article
  15. Prevalence of CTX-M types among ESBL-producing pathogenicFood science and biotechnology · 2024
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Isabel CarvalhoMicrobiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.ORCID 0000-0003-1762-412X
José António CarvalhoMedical Center of Trás-os-Montes e Alto Douro E.P.E., 5000-508 Vila Real, Portugal.
Sandra Martínez-ÁlvarezArea Biochemistry and Molecular Biology, University of La Rioja, 26006 Logroño, Spain.ORCID 0000-0003-3756-710X
Madjid SadiArea Biochemistry and Molecular Biology, University of La Rioja, 26006 Logroño, Spain.
Rosa CapitaDepartment of Food Hygiene and Technology, Veterinary Faculty, University of León, 24071 León, Spain.ORCID 0000-0001-9584-0755
Carlos Alonso-CallejaDepartment of Food Hygiene and Technology, Veterinary Faculty, University of León, 24071 León, Spain.ORCID 0000-0002-8688-0912
Fazle RabbiAustralian Computer Society, Melbourne 3008, Australia.ORCID 0000-0002-5974-7905
Maria de Lurdes Nunes Enes DapkeviciusFaculty of Agricultural and Environmental Sciences, University of the Azores, 9500-321 Angra do Heroísmo, Portugal.ORCID 0000-0003-2146-5627
Gilberto IgrejasDepartment of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.ORCID 0000-0002-6365-0735
Carmen TorresArea Biochemistry and Molecular Biology, University of La Rioja, 26006 Logroño, Spain.ORCID 0000-0003-3709-1690
Patrícia PoetaMicrobiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro, 5000-801 Vila Real, Portugal.

Funding

Agencia Estatal de Investigation (AEI) of Spain and FEDER of EU SAF2016-76571-RFundação para a Ciência e a Tecnologia SFRH/BD/133266/2017 (Medicina Clínica e Ciências da Saúde)Fundação para a Ciência e a Tecnologia UIDB/50006/2020 and UIDP/50006/2020
6 · The paper itself

Abstract

background

methodsA total of 62 cefotaxime/ceftazidime-resistant

resultsESBL activity was detected in all 62

conclusionsDifferent ESBL variants of CTX-M (especially CTX-M-15) and SHV-type (specially SHV-12) were detected among CTX/CAZ

Indexed as

antimicrobial resistanceCarbapenemasesCTX-M-15Escherichia colihumanKlebsiella pneumoniaeKPC2/3Portugalpublic healthβ-lactamases

Identifiers

PMID34576808
PMCPMC8467980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.